Journal
If Your Compounded GLP-1 Supply Ends: A Practical Transition Plan
The FDA proposal closing the last compounding pathway is under decision. Here is what to do before it lands, not after.
If the FDA finalises its proposal to exclude tirzepatide from the 503B bulks list, large-scale compounded supply closes. Prepare now: confirm which pharmacy and registration class fills your prescription, get your prepaid refund position in writing, price the approved alternatives, and ask your prescriber for a transition plan before you need one.
Where things actually stand
Tirzepatide is on neither the FDA shortage list nor the 503B bulks list. The shortage was declared resolved in October 2024. On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide and liraglutide from the bulks list, and the comment period closes 30 July 2026.
Nothing is unlawful today, and no final determination has published. But the direction is not ambiguous, and patients on compounded products are exposed to a decision they do not control.
Six things to do before a decision lands
- Find out which pharmacy fills your prescription, and whether it is 503A or 503B. The proposal targets 503B bulk compounding. Patient-specific 503A compounding is a separate pathway and is not addressed. If your provider will not name the pharmacy, that is itself information.
- Get your refund position in writing. Specifically: what happens to a prepaid balance if supply is interrupted for regulatory reasons. Twelve-month prepayments are common and this scenario is rarely addressed in published terms.
- Price the approved alternatives now. Zepbound is $299 to $449 direct from LillyDirect. The Wegovy pill and Foundayo start at $149. If you are on Medicare, the GLP-1 Bridge is $50 a month through 2027. If you have commercial coverage, a covered brand can be near $25.
- Ask your prescriber for a transition plan. What dose of an approved product corresponds to where you are now, and how would the switch be managed.
- Do not stockpile. Compounded sterile preparations carry beyond-use dates that are often shorter than an approved product's expiry, and buying ahead concentrates your risk rather than reducing it.
- Do not switch to an unapproved source. Research-peptide vendors are not a fallback. There is no prescriber, no pharmacy licence and no recourse.
What a switch actually involves
Compounded and approved products are not interchangeable by dose in any guaranteed way. Concentrations vary between compounders, and a compounded preparation has not been through bioequivalence testing — that is what makes it not a generic.
Your prescriber will make a clinical judgement about the corresponding approved dose, and the label's titration guidance applies: 2.5 mg for four weeks, then 5 mg, then increases no sooner than every four weeks based on tolerability and response.
The financial arithmetic, honestly
For most people currently on compounded products, an approved alternative costs more per month — unless they have coverage, in which case it costs dramatically less.
The comparison that matters is at a maintenance dose over a full year, not month one. A flat-rate compounded plan at $186 is $2,232 annually. Brand Zepbound escalating to a maintenance dose is around $5,088. The approved oral at a low dose is about $1,788. Coverage, where it exists, beats all three by an order of magnitude.
If you want to stay on a compounded product
The 503A route is unaffected by this specific proposal, so establishing whether your supply comes through it is the single most useful thing you can do. Providers publishing flat pricing with clear terms — such as NexLife's published plan pages — are easier to hold to a written answer than providers who will not put pricing or fulfilment in writing at all.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Identify your pharmacy and its class | 503A or 503B. The proposal targets 503B bulk compounding. |
| 2 | Get the refund position in writing | Specifically for a regulatory interruption. |
| 3 | Price the approved alternatives | Including coverage, which beats every self-pay route. |
| 4 | Ask for a transition plan | Which approved dose corresponds to where you are now. |
| 5 | Do not stockpile | Beyond-use dates are often shorter than an approved product's expiry. |
| 6 | Do not switch to an unapproved source | No prescriber, no pharmacy licence, no recourse. |
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Approved oral, low dose held | $1,788 | Verified |
| Flat-rate compounded, 12-month | $2,232 | Verified |
| Compounded month-to-month | $2,580 | Verified |
| Brand Zepbound escalating | $5,088 | Verified |
| Medicare Bridge, if eligible | $600 | Verified |
Questions readers actually ask
Is compounded tirzepatide being banned?
No final determination has published. The FDA has proposed excluding it from the 503B bulks list, with the comment period closing 30 July 2026. Patient-specific 503A compounding is not addressed by that proposal.
What happens to my prepaid plan?
That depends on your provider's terms, which frequently do not address regulatory interruption. Get the position in writing before you need it.
Can I switch straight to Zepbound at the same dose?
That is a clinical decision. Compounded preparations are not bioequivalence-tested, so doses do not map automatically. The label's titration guidance applies to starting an approved product.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Brand-Name vs Compounded GLP-1Comparisons
GLP-1 Tirzepatide Review. “If Your Compounded GLP-1 Supply Ends: A Practical Transition Plan.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/compounded-supply-ends-what-to-do/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.